Development of a synbiotic dietary supplement containing potential Next Generation Probiotics for modulation of the gut microbiome and metabolome.

Our assessment

This 2026 study focused on developing a new type of dietary supplement, called a synbiotic, which combines a prebiotic with specific live bacteria. The researchers analyzed 14 different bacterial strains taken from the gut microbiomes of healthy individuals. They wanted to see which strains could produce beneficial compounds like urolithins, equol, and short-chain fatty acids (SCFAs). This is a laboratory-based characterization study — it did not involve human participants, so there is no sample size or study duration to report. The data provided does not list the authors NIH ODS ↗.

How it works

The researchers identified the 4 most promising bacterial strains: Bacteroides uniformis A4 and Bacteroides thetaiotaomicron (the abstract cuts off, so full details are not available). These are considered "Next Generation Probiotics" because they are not the typical lactic acid bacteria found in yogurt. The goal is to create a supplement that helps your gut microbiome produce substances like SCFAs, which are known to support gut health and metabolism. What this means for you: this is early-stage research looking at which specific bacteria might be best for a future supplement, but it is not ready for human use yet NIH ODS ↗.

Safety profile

Data not available. The provided information does not include any FDA adverse event reports or side effect data for this specific synbiotic supplement FDA FAERS ↗.

Our recommendation

This is a very early, preclinical study. Because it was done in a lab and not in humans, there is not enough evidence to recommend this specific supplement. Stick with well-studied probiotics that have human trial data supporting their safety and effectiveness. Always talk to your doctor before trying a new supplement NIH ODS ↗ FDA FAERS ↗.